Clinical application and challenge of liquid biopsy in the precision medicine of colorectal cancer

doi:10.3969/j.issn.1006-7795.2017.06.001

Abstract

Abstract: With the rapid development of precision medicine in cancer,the demand for dynamic monitoring of tumor molecular characteristic has been increased. In recent years, liquid biopsy is currently playing a more and more important role in diagnosis and treatment of cancer in clinical practice due to its convenience, non-invasiveness, high specificity and overcoming temporal-spatial heterogeneity. This review introduces circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) as the most important technique in liquid biopsy, mainly focusing on their technological feature, especially recent research progress in colorectal cancer. Further, the challenge and possible solution are discussed in the clinic application of liquid biopsy.

Key words: liquid biopsy, colorectal cancer, circulating tumor cells, circulating tumor DNA

CLC Number:

R735.3

Yang Yingchi, Zhang Zhongtao. Clinical application and challenge of liquid biopsy in the precision medicine of colorectal cancer[J]. Journal of Capital Medical University, 2017, 38(6): 785-789.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2017.06.001

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2017/V38/I6/785

References

[1] Ryuk J P, Choi G S, Park J S, et al. Predictive factors and the prognosis of recurrence of colorectal cancer within 2 years after curative resection[J]. Ann Surg Treat Res, 2014, 86(3):143-151.
[2] Ignatiadis M, Lee M, Jeffrey S. Circulating tumor cells and circulating tumor DNA:challenges and opportunities on the path to clinical utility[J]. Clin Cancer Res,2015,21(21):4786-4800.
[3] Lowes L E, Bratman S V, Dittamore R, et al. Circulating tumor cells (CTC) and Cell-free DNA (cfDNA) Work Shop 2016:scientific opportunities and logistics for cancer clinical trial incorporation[J]. Int J Mol Sci,2016,17(9):pii:E1505.
[4] Galatea K, Eleni P, Saad A, et al. Evaluation of isolation methods for circulating tumor cells (CTCs)[J]. Cell Physiol Biochem,2016, 40:411-419.
[5] Dive C, Brady G. Snap shot:circulating tumor cells[J]. Cell, 2017,169(1):176.
[6] Newman A M, Bratman S V, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage[J]. Nat Med,2014, 20(5):548-554.
[7] Wong S C, Chan C M, Mab B, et al. Clinical significance of cytokeratin 20-positive circulating tumor cells detected by a refined immunomagnetic enrichment assay in colorectal cancer patients[J]. Clin Cancer Res,2009, 15(3):1005-1012.
[8] Sastre J, Maestro M L, Puente J, et al. Circulating tumor cells in colorectal cancer:correlation with clinical and pathological variables[J]. Ann Oncol, 2008, 19(5):935-938.
[9] Amin M B, Edge S, Greene F, et al. AJCC cancer staging manual[M]. 8th. New York:Springer, 2017.
[10] Galizia G, Gemei M, Orditura M, et al. Postoperative detection of circulating tumor cells predicts tumor recurrence in colorectal cancer patients[J]. J Gastrointest Surg,2013,17(10):1809-1818.
[11] Nesteruk D, Rutkowski A, Fabisiewicz S, et al.Evaluation of prognostic significance of circulating tumor cells detection in rectal cancer patients treated with preoperative radiotherapy:prospectively collected material data[J]. Biomed Res Int, 2014, 2014:712827.
[12] Rahbari N N, Aigner M, Thorlund K, et al. Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer[J]. Gastroenterology, 2010, 138(5):1714-1726.
[13] Van Dalum G, Stam G J, Scholten L F, et al. Importance of circulating tumor cells in newly diagnosed colorectal cancer[J]. Int J Oncol,2015, 46(3):1361-1368.
[14] Barbazán J, Muinelo-Romay L, Vieito M, et al. A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer[J]. Int J Cancer, 2014, 135(11):2633-2643.
[15] Church T R, Wandell M, Lofton-Day C, et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer[J]. Gut,2014, 63(2):317-325.
[16] Arena S, Siravegna G, Mussolin B, et al. MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations[J]. Sci Translat Med, 2016,8(324):314-324.
[17] Diaz L J, Williams R T, Wu J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers[J]. Nature,2012,486(7404):537-540.
[18] Lecomte T, Berger A, Zinzindohou F, et al. Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis[J]. Int J Cancer,2002, 100(5):542-548.